ROS1 and non-small cell lung carcinoma: ROS1 inhibitors such as Crizotinib, Cabozantinib, and Ceritinib have demonstrated significant efficacy in the treatment of ROS1-positive tumors, providing valuable therapeutic options for patients with advanced non–small cell lung cancer (NSCLC).